JO3225B1 - 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 - Google Patents
6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8Info
- Publication number
- JO3225B1 JO3225B1 JOP/2013/0331A JOP20130331A JO3225B1 JO 3225 B1 JO3225 B1 JO 3225B1 JO P20130331 A JOP20130331 A JO P20130331A JO 3225 B1 JO3225 B1 JO 3225B1
- Authority
- JO
- Jordan
- Prior art keywords
- tarp
- receptor antagonist
- benzothiazol
- pyrazol
- pyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
يتعلق الاختراع الحالي بمضاد مستقبل AMPA يعتمد على TARP- ?8 له الصيغة: وأملاحه المقبولة صيدليًا، واستخداماته، وطرق تحضيره.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730273P | 2012-11-27 | 2012-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3225B1 true JO3225B1 (ar) | 2018-03-08 |
Family
ID=49753484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2013/0331A JO3225B1 (ar) | 2012-11-27 | 2013-11-17 | 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8765960B2 (ar) |
| EP (1) | EP2925754B1 (ar) |
| JP (1) | JP6246227B2 (ar) |
| KR (1) | KR101693133B1 (ar) |
| CN (1) | CN104797578B (ar) |
| AP (1) | AP2015008489A0 (ar) |
| AR (1) | AR093527A1 (ar) |
| AU (1) | AU2013352594B2 (ar) |
| BR (1) | BR112015011200A2 (ar) |
| CA (1) | CA2889243C (ar) |
| CL (1) | CL2015001419A1 (ar) |
| CR (1) | CR20150267A (ar) |
| CY (1) | CY1118657T1 (ar) |
| DK (1) | DK2925754T3 (ar) |
| DO (1) | DOP2015000113A (ar) |
| EA (1) | EA026686B1 (ar) |
| ES (1) | ES2618260T3 (ar) |
| HK (1) | HK1209116A1 (ar) |
| HR (1) | HRP20170274T1 (ar) |
| HU (1) | HUE033447T2 (ar) |
| IL (1) | IL238831B (ar) |
| JO (1) | JO3225B1 (ar) |
| MA (1) | MA38126B1 (ar) |
| MX (1) | MX356478B (ar) |
| MY (1) | MY177721A (ar) |
| PE (1) | PE20151728A1 (ar) |
| PH (1) | PH12015501154A1 (ar) |
| PL (1) | PL2925754T3 (ar) |
| PT (1) | PT2925754T (ar) |
| SG (1) | SG11201504164VA (ar) |
| SI (1) | SI2925754T1 (ar) |
| TN (1) | TN2015000200A1 (ar) |
| TW (2) | TWI618705B (ar) |
| UA (1) | UA114345C2 (ar) |
| WO (1) | WO2014085153A1 (ar) |
| ZA (1) | ZA201503733B (ar) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201609719A (zh) * | 2014-05-28 | 2016-03-16 | 美國禮來大藥廠 | 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物 |
| US10513523B2 (en) | 2015-04-29 | 2019-12-24 | Janssen Pharmaceutica Nv | Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators |
| CR20170484A (es) * | 2015-04-29 | 2018-02-26 | Jansen Pharmaceutical Nv | Azabenzimidazoles y su uso como moduladores del receptor ampa |
| CN107635970B (zh) * | 2015-04-29 | 2021-03-12 | 詹森药业有限公司 | 苯并咪唑酮和苯并噻唑酮化合物以及它们作为ampa受体调节剂的用途 |
| KR20170141769A (ko) | 2015-04-29 | 2017-12-26 | 얀센 파마슈티카 엔.브이. | 인돌론 화합물 및 ampa 수용체 조절제로서의 이의 용도 |
| CN109963851B (zh) * | 2016-10-26 | 2021-11-30 | 詹森药业有限公司 | 融合的双环吡啶化合物及其作为ampa受体调节剂的用途 |
| RU2650523C1 (ru) * | 2017-07-24 | 2018-04-16 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Производное пиридоксина для лечения эпилепсии |
| RU2703286C1 (ru) * | 2019-06-18 | 2019-10-16 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Соли (5-гидрокси-3,4-бис(гидроксиметил)-6-метилпиридин-2-ил)метансульфокислоты и способ их получения |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY132385A (en) * | 1995-08-31 | 2007-10-31 | Novartis Ag | 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives |
| JP2000281676A (ja) * | 1999-01-25 | 2000-10-10 | Yamanouchi Pharmaceut Co Ltd | Ａｍｐａ拮抗化合物の新規製造法 |
| KR100850728B1 (ko) * | 2000-06-12 | 2008-08-06 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 1,2-디하이드로피리딘 화합물, 그의 제조 방법 및 그의 용도 |
| US8995993B2 (en) * | 2000-10-11 | 2015-03-31 | Gogo Llc | System for managing mobile internet protocol addresses in an airborne wireless cellular network |
| AU2005316313B2 (en) * | 2004-12-17 | 2011-09-29 | Eli Lilly And Company | Novel MCH receptor antagonists |
| WO2007076161A2 (en) | 2005-12-27 | 2007-07-05 | Myriad Genetics, Inc | Compounds with therapeutic activity |
| TW200817385A (en) * | 2006-07-04 | 2008-04-16 | Organon Nv | Heterocyclic derivatives |
| CA2739559A1 (en) * | 2008-10-08 | 2010-04-15 | Pfizer Inc. | Tetrahydrofuranyl sulfonamides and pharmaceutical compositions thereof |
| PT2385938E (pt) * | 2009-01-12 | 2015-06-02 | Pfizer Ltd | Derivados de sulfonamida |
| US8513291B2 (en) * | 2010-06-01 | 2013-08-20 | Angion Biomedica Corp. | Cytochrome P450 inhibitors and uses thereof |
| US9527807B2 (en) * | 2011-04-05 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| TW201609719A (zh) * | 2014-05-28 | 2016-03-16 | 美國禮來大藥廠 | 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物 |
-
2013
- 2013-11-17 JO JOP/2013/0331A patent/JO3225B1/ar active
- 2013-11-18 AR ARP130104242A patent/AR093527A1/es unknown
- 2013-11-18 TW TW102141949A patent/TWI618705B/zh not_active IP Right Cessation
- 2013-11-18 TW TW106144388A patent/TW201825484A/zh unknown
- 2013-11-20 KR KR1020157013470A patent/KR101693133B1/ko active IP Right Grant
- 2013-11-20 AP AP2015008489A patent/AP2015008489A0/xx unknown
- 2013-11-20 US US14/084,683 patent/US8765960B2/en active Active
- 2013-11-20 MX MX2015006697A patent/MX356478B/es active IP Right Grant
- 2013-11-20 AU AU2013352594A patent/AU2013352594B2/en active Active
- 2013-11-20 BR BR112015011200A patent/BR112015011200A2/pt not_active IP Right Cessation
- 2013-11-20 DK DK13802786.7T patent/DK2925754T3/en active
- 2013-11-20 SG SG11201504164VA patent/SG11201504164VA/en unknown
- 2013-11-20 MA MA38126A patent/MA38126B1/fr unknown
- 2013-11-20 UA UAA201504865A patent/UA114345C2/uk unknown
- 2013-11-20 EA EA201590823A patent/EA026686B1/ru not_active IP Right Cessation
- 2013-11-20 CN CN201380061495.2A patent/CN104797578B/zh active Active
- 2013-11-20 PT PT138027867T patent/PT2925754T/pt unknown
- 2013-11-20 JP JP2015545099A patent/JP6246227B2/ja active Active
- 2013-11-20 WO PCT/US2013/070885 patent/WO2014085153A1/en active Application Filing
- 2013-11-20 PE PE2015000694A patent/PE20151728A1/es active IP Right Grant
- 2013-11-20 EP EP13802786.7A patent/EP2925754B1/en active Active
- 2013-11-20 ES ES13802786.7T patent/ES2618260T3/es active Active
- 2013-11-20 MY MYPI2015701544A patent/MY177721A/en unknown
- 2013-11-20 PL PL13802786T patent/PL2925754T3/pl unknown
- 2013-11-20 CA CA2889243A patent/CA2889243C/en active Active
- 2013-11-20 SI SI201330464A patent/SI2925754T1/sl unknown
- 2013-11-20 HU HUE13802786A patent/HUE033447T2/en unknown
-
2015
- 2015-05-14 DO DO2015000113A patent/DOP2015000113A/es unknown
- 2015-05-14 IL IL238831A patent/IL238831B/en not_active IP Right Cessation
- 2015-05-20 CR CR20150267A patent/CR20150267A/es unknown
- 2015-05-22 TN TNP2015000200A patent/TN2015000200A1/fr unknown
- 2015-05-25 PH PH12015501154A patent/PH12015501154A1/en unknown
- 2015-05-26 CL CL2015001419A patent/CL2015001419A1/es unknown
- 2015-05-26 ZA ZA2015/03733A patent/ZA201503733B/en unknown
- 2015-10-08 HK HK15109825.5A patent/HK1209116A1/xx not_active IP Right Cessation
-
2017
- 2017-02-20 HR HRP20170274TT patent/HRP20170274T1/hr unknown
- 2017-02-24 CY CY20171100252T patent/CY1118657T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501154A1 (en) | 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}-ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist | |
| PH12019502074A1 (en) | Sustained release dosage forms for a jak1 inhibitor | |
| PH12014502169A1 (en) | N-cyclylamides as nematicides | |
| MY181898A (en) | Heterocyclic compounds and uses thereof | |
| WO2012077136A3 (en) | Process for the preparation of benzimidazole derivatives and its salts | |
| MY195209A (en) | Partially Saturated Nitrogen-Containing Heterocyclic Compound | |
| MX336247B (es) | Derivados de amida heterociclicos como antagonistas del receptor p2x7. | |
| MY176244A (en) | Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist | |
| GB201101517D0 (en) | Receptor antagonists | |
| PH12015501146A1 (en) | Hydantoin derivative | |
| MX345142B (es) | Derivados de aminoalquilpirimidina como antagonistas del receptor h4 de histamina. | |
| PH12014501760B1 (en) | Method for stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro[5.5]undecanes | |
| TN2011000588A1 (en) | Novel pharmaceutically acceptable salts of 4-(1h-imidazol-4-ylmethyl) pyridine and their therapeutical uses | |
| WO2012094437A3 (en) | Nicotinic receptor non-competitive antagonists |